NOVEL DRUG DELIVERY SYSTEM THROUGH NASAL (NON-INVASIVE)
DOI:
https://doi.org/10.22159/ajpcr.2018.v11s4.31705Keywords:
Intranasal, First-pass metabolism, Mucoadhesion, BioavailabilityAbstract
Intranasal route is the best method for high absorption and direct delivery to the brain. The interests and importance, of this route, are that the systemic effects of drugs when administered through the nasal route, have expanded over recent decades and it used for therapeutic and recreational purposes. In comparison with the parenteral route of drug administration, intra-nasal administration of drugs offers an interesting alternative for achieving systemic therapeutic effects of drugs. The oral administration of the drug produces low drug bioavailability, and this can be minimized using this nasal route. Moreover, the advantage of this route is that it can bypass the first-pass metabolism. Therefore, it is important to understand the potential and limitations of various nasal drug delivery systems. The aim of this review article is to discuss the various pharmaceutical dosage forms that have the potential to be utilized for local or systemic drug administration. It is assumingly expected that this review will help to understand about this route and also to develop suitable intra-nasal formulations to achieve specific therapeutic objectives. The different types of nasal drug formulations that can be used are nasal drops, nasal sprays, nasal gels, nasal suspensions and emulsion, and nasal powders.
Downloads
References
Alagusundaram M, Chengaiah B, Gnanaprakash K, Ramkanth S, Chetty MC, Dhachinamoorthi D. Nasal drug delivery system. Int J Pharm Sci 2010;1:454-65.
Ghoril MU, Mahdi MH, Smith AM, Barbara R. Conway nasal drug delivery system. Am Pharm Sci 2015;3:5.
Satyanarayana U. Textbook of Biochemistry. Amsterdam: Elsevier Science; 2004. p. 9.
Himi T, Takano K editors. Excellence in Otolaryngology of Sapporo Medical University. Basel: Karger; 2016. p. 88-91.
Reddy LP. Fundamentals of Medical Physiology. 5th ed. Oxford: Oxford University Press; 2013. p. 526.
Aulton ME, Taylor K. Aulton’s Pharmaceutics and Design and Manufacture of Medicines. Edinburgh: Churchill, Living Stone; 2015.
Chien YW, Chang SF. International drug delivery system of systemic medications. Crit Rev Ther Drug Carrier Syst 1987;4:67-194.
Chien YW, SU KS, Chang SF. Anatomy and physiology of nose. In: Chen YW, SU KS, Chang SF, editors. Nasal Systemic Drug Delivery Drug and Pharmaceutical Science. Vol. 39. New York: Marcel Dekker; 1989. p. 1-19.
Singh L, Khan AD. Nasal drug delivery; a promising way for brain targeting. Pharm Res 2013;13:1-12.
Prajapati ST, Pathak SP, Thakkar JH, Patel CN. Nanoemulsion based internasal delivery of risperidone for nose to brain targeting. Bull Pharm Res 2015;5:6.
Mundlia J, Mukesh K. Nasal drug delivery, an overview. Int J Pharm Sci Res 2015;5:951-6.
UgWoke MI, Verbeke N, Kinget R. The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J Pharm Pharmacol 2001;53:3-22.
Ozsoy Y, Tunçel T, Can A, Akev N, Birteksöz S, Gerçeker A, et al. In vivo studies on nasal preparations of ciprofloxacin hydrochloride. Pharmazie 2000;55:607-9.
Electronic Medicines Compendium. Database on Internet Datapharm Communications Ltd.; 2015. Available from: http://www.emc.medicines.org.uk.
Eller N, Kollenz CJ, Bauer P, Hitzenberger G. The duration of antidiuretic response of two desmopressin nasal sprays. Int J Clin Pharmacol Ther 1998;36:494-500.
Knoester PD, Jonker DM, Hoeven RT, Vermeij TA, Edelbroek PM, Brekelmans GJ, et al. Pharmacokinetics and pharmacodynamics of midazolam administred as concentrated intranasal spray. A study in health volunteers. Br J Clin Pharmacol 2000;53:501-7.
Vidgren MT, Kublik H. Nasal delivery systems and their effect on deposition and absorption. Adv Drug Deliv Rev 1998;29:157-77.
Merkus FW, Schipper NG, Hermens WA, Romeijns SG, Verholf JC. Absorption enhancers in nasal drug delivery; efficacy and safety. J Control Release 1993;24:201-8.
Natsume H, Iwata S, Miyamoto M, Kawai T, Sugibayashi K, Morimoto Y. Screening of absorption enhances for nasal peptide and protein delivery proceed internet symp. Control Release Bioact Mater 1996;23:481-2.
Zhou M, Donovan MD. Recovery of nasal mucosa following laureth-9 induced damage. Int J Pharm 1996;130:93-102.
Chandler SG, Illum L, Thomas NW. Nasal absorption in rats II effects of enhances on insulin absorption and nasal histology. Int J Pharm 1991;76:61-70.
Chandler SG, Illum L, Thomas NW. Nasal absorption in rats III lysophospholipids on insulin absorption and nasal histology. Pharm Res 1991;11:1623-30.
Aungst BJ, Rogers NJ, Sheffer E. Comparison of nasal, rectal, buccal sublingual and intramuscular insulin efficacy effects of bile salts absorption promotor. J Pharmacol Exp Ther 1998;224:23-7.
Yamamoto A, Morita T, Hashida M, Sezaki H. Effects of absorption promotors on nasal absorption of drug with various molecular weight. Int J Pharm 1993;93:91-9.
Bagger MA, Nielsen HW, Bechgaard E. Nasal bioavailability of peptide T in rabbits absorption enhancement by sodium glycolate and glycofural. Eur J Pharm Sci 2001;14:69-74.
Davis SS Illum L. Absorption enhancers for nasal drug delivery. Clin Pharmacokinet 2003;42:1107-28.
Touitou E, Barry BW, editors. Enhancement in Drug Delivery. Boca Raton: CRC press; 2006.
Marttin E, Verhoef JC, Merkus FW. Efficacy safety and mechanism of cyclodextrins as absorption enhancers in nasal drug delivery of peptide and protein drug. J Drug Target 1998;6:17-36.
Matsubara K, Abe K, Irie T, Uekama K. Improvement of nasal bioavailability of LH Hormone releasing agonist, buserelin by cyclodextrin derivatives in rats. J Pharm Sci 1995;84:1295-300.
Ugwoke MI, Agu RU, Verbeke N, Kinget R. Nasal mucoadhesive drug delivery; background application trends and future perspectives . Adv Drug Deliv Rev 2005;57:1640-65.
Vyas TK, Shahiwala A, Marathe S, Misra A. Intranasal drug delivery for brain targeting. Curr Drug Deliv 2005;2:165-75.
Hanson LR, Frey WH 2nd. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci 2008;9 Suppl 3:S5.
Romeo VD, deMeireles J, Sileno AP, Pimplaskar HK, Behl CR. Effects of physicochemical properties and other factors on systemic nasal drug delivery. Adv Drug Deliv Rev 1998;29:89-116.
Chaturvedi M, Kumar M, Pathak K. A review on mucoadhesive polymer used in nasal drug delivery system. J Adv Pharm Technol Res 2011;2:215-22.
Harris AS. Review: Clinical opportunities provided by the nasal administration of peptides. J Drug Target 1993;1:101-16.
Hussein NR. Bio Adhesive Micro Particles and Liposomes of Anti Parkinson Drugs for Nasal Delivery. PhD Thesis University of Central Lanceshire; 2014.
Singh AK, Singh A, Madhv NV. Nasal cavity a pro messing trans mucosal. Platform for drug delivery and research approaches from nasal to brain. J Drug Deliv Ther 2012;2:22-33.
Jadhav K R, Gambhire MN, Shaikh IM, Kadam VJ, Pisal SS. Nasal drug delivery system-factors affecting and application. Curr Drug Ther 2007;2:27-38.
Suman JD. Nasal drug delivery. Expert Opin Biol Ther 2003;3:519-23.
Alagusundaram M, Chengaiah B, Gnanaprakash K, Ramkanth S, Chetty CM, Dhachinamoorthi D. Nasal drug delivery system an overview. Int J Res Pharm Sci 2015;1:454-65.
Sintov AC, Levy HV, Botner S. Systemic delivery of insulin via the nasal route using a new micro emulsion system; in vitro and in vivo studies. J Control Release 2001;148:168-76.
Upadhyay S, Parikh A, Joshi P, Upadhyay UM, Chotai NP. Intra nasal drug delivery system a glimpse to become maestro. J Appl Sci 2011;1:34-44.
Huang CH, Kimura R, Nassar RB, Hussain A. Mechanism of nasal absorption of drugs I: Physicochemical parameters influencing the rate of in situ nasal absorption of drugs in rats. J Pharm Sci 1985 ; 74:608-11.
Shinichiro H, Takatsuka Y, Hiroyuki M. Mechanism for the enhancement of the nasal absorption of insulin by surfactants. Int J Pharm 1981;9:173-84.
Duvvuri S, Majumdar S, Mitra AK. Drug delivery to the retina: Challenges and opportunities. Expert Opin Biol Ther 2003;3:45-56.
Brahmankar DM. Textbook of Biopharmaceutics and Pharmacokinetic. New York: McGraw-Hill; 2018. p. 11.
Mahdi MH, Conway BR, Smith AM. Development of mucoadhesive sprayable gellan gum fluid gels. Int J Pharm 2015;488:12-9.
Washington N, Washington C, Wilson CG. Physiological Pharmaceutics Barrier to Drug Absorption. New York: Taylor and Francis; 2011.
Djupesland PG. Nasal drug delivery devices: Characteristics and performance in a clinical perspective-a review. Drug Deliv Transl Res 2013;3:42-62.
Hansen K, Kim G, Desai KG, Patel H, Olsen KF, Curtis-Fisk J, et al. Feasibility investigation of cellulose polymers for mucoadhesive nasal drug delivery applications. Mol Pharm 2015;12:2732-41.
Rassu G, Soddu E, Cossu M, Brundu A, Cerri G, Marchetti N, et al. Solid microparticles based on chitosan or methyl-β-cyclodextrin: A first formulative approach to increase the nose-to-brain transport of deferoxamine mesylate. J Control Release 2015;201:68-77.
Menaka M, Pandey VP. Formulation development and evaluation of cinnarizine nasal spray. Pharm Health Sci 2014;2:339-46.
Rathbone MJ, Hadgraft J, Roberts MS, editors. Modified Release Drug Delivery Technology. Boca Raton: CRC Press; 2002.
Nakumura K, Tanaka Y, Sakurai M. Dynamic mechanical properties of aqueous gellan solution sol-gel transition region. Carbohydr Polym 1996;30:101-8.
Patil SB, Sawant KK. Mucoadhesive microsphere; a promising tool in drug delivery. Curr Drug Deliv 2008;5:312-8.
Pasha M, Ngn S. Derivatization of guar to sodium carboxy methyl hydroxy propyl derivative; characterization and evaluation. Pak J Pharm Sci 2008;21:40-4.
Zitt M, Kosoglou T, Hubbell J. Mometasone furoate nasal spray: A review of safety and systemic effects. Drug Saf 2007;30:317-26.
Saindane NS, Pagar KP, Vavia PR. Nanosuspension based in situ gelling nasal spray of carvedilol: Development, in vitro and in vivo characterization. AAPS PharmSciTech 2013;14:189-99.
Vila A, Sánchez A, TobÃo M, Calvo P, Alonso MJ. Design of biodegradable particles for protein delivery. J Control Release 2002;78:15-24.
Davis SS. Nasal vaccines. Adv Drug Deliv Rev 2001;51:21-42.
Madan M, Lewis MB, Udupa S, Baig N. In situ forming polymeric drug delivery system. Indian J P S 2009:71;242-51.
Sworn G, Sanderson GR, Gibson W. Gellan gum fluid gel. Food Hydrocoll 1995;9:265-71.
Doi K. U.S Patent No. 6. 368-616. Washington, DC: US Patent and Trademark Office; 2002.
Ando T, Maitani Y, Yamamoto T, Takayama K, Nagai T. Nasal insulin delivery in rabbits using soyabean derivatives sterylglycoside and sterol mixturea are novel enhancers in suspension dosage forms. Biol Pharm Bull 1996;21:862-65.
Aikawa K, Matsumoto K, Uda H, Tanaka S, Shimamura H, Aramaki Y, et al. Prolonged release of drug from O/w emulsion and residence in rat nasal cavity. Pharm Dev Technol 1998;3:461-9.
Tamilvanan S. O/W Nanosized Emulsion, Medical Application Polymer Science Encyclopedia. New York: John Wiley Sons Inc.; 2008.
Kararli TT, Needham TE, Griffin M, Schoenhard G, Ferro LJ, Alcorn L, et al. Oral delivery of a renin inhibitor compound using emulsion formulations. Pharm Res 1992;9:888-93.
Kararli TT, Needham TE, Schoenhard G, Baron DA, Schmidt RE, Katz B, et al. Enhancement of nasal delivery of a renin inhibitor in the rat using emulsion formulations. Pharm Res 1992;9:1024-8.
Li L, Nandi I, Kim KH. Development of an ethyl laurate-based microemulsion for rapid-onset intranasal delivery of diazepam. Int J Pharm 2002;237:77-85.
Zhang X, Wu B. Sub micron lipid emulsion; a versatile platform for drug delivery. Curr Drug Metab 2015;16:211-20.
Shinde RL, Bharkad GP, Devarajan PV. Intranasal microemulsion for targeted nose to brain delivery in neurocysticercosis: Role of docosahexaenoic acid. Eur J Pharm Biopharm 2015;96:363-79.
Yadav S, Gattacceca F, Panicucci R, Amiji MM. Comparative biodistribution and pharmacokinetic analysis of cyclosporine-a in the brain upon intranasal or intravenous administration in an oil-in-water nanoemulsion formulation. Mol Pharm 2015;12:1523-33.
Takenaga M, Serizawa Y, Azechi Y, Ochiai A, Kosaka Y, Igarashi R, et al. Microparticle resins as a potential nasal drug delivery system for insulin. J Control Release 1998;52:81-7.
Ishikawa E, Yanaka K, Sugimoto K, Ayuzawa S, Nose T. Reversible dementia in patients with chronic subdural hematomas. J Neurosurg 2002;96:680-3.
Illum L, Farraj NF, Davis SS. Chitosan as a novel nasal delivery system for peptide drugs. Pharm Res 1994;11:1186-9.
Ugwoke MI, Agu RU, Vanbilloen H, Baetens J, Augustijns P, Verbeke N, et al. Scintigraphic evaluation in rabbits of nasal drug delivery systems based on carbopol 971p((R)) and carboxymethylcellulose. J Control Release 2000;68:207-14.
Callens C, Remon JP. Evaluation of starch-maltodextrin-carbopol 974 P mixtures for the nasal delivery of insulin in rabbits. J Control Release 2000;66:215-20.
Oechslein CR, Fricker G, Kissel T. Nasal delivery of octerotide; absorption enhancement by particulate carrier system. Int J Pharm 1996;138:25-32.
Nagai K, Thogersen HC, Generation of beta-globin by sequence specific disteolysis of a hybrid protein produced in E.coli nature 1984;308:810-2.
Ikechukwu Ugwoke M, Sam E, Van Den Mooter G, Verbeke N, Kinget R. Nasal mucoadhesive delivery systems of the anti-parkinsonian drug, apomorphine: Influence of drug-loading on in vitro and in vivo release in rabbits. Int J Pharm 1999;181:125-38.
Callens C, Pringels E, Remon JP. Influence of multiple nasal administrations of bioadhesive powders on the insulin bioavailability. Int J Pharm 2003;250:415-22.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
